Analysis on the efficiency of the therapeutic strategies in TA-TMA patients
| Strategies . | N . | TA-TMA response . | N . | Post TA-TMA survival . | ||||
|---|---|---|---|---|---|---|---|---|
| Response rate, % . | OR (95% CI) . | P . | Median OS, d . | HR (95% CI) . | P . | |||
| Immunosuppressant modulation | ||||||||
| Maintenance/reduction of CNI | 85 | 64.7 | Reference | 86 | 50 | Reference | ||
| Switch to other CNIs | 11 | 72.7 | 1.42 (0.35-5.89) | .62 | 11 | 74 | 0.71 (0.35-1.44) | .34 |
| Switch to CS | 10 | 20.0 | 0.12 (0.02-0.63) | .01* | 11 | 17 | 3.23 (1.64-6.33) | <.01* |
| Increase of CS | 9 | 44.4 | 0.37 (0.09-1.59) | .18 | 10 | 36 | 1.71 (0.86-3.42) | .13 |
| rhTM | ||||||||
| N | 83 | 59.0 | Reference | 85 | 41 | Reference | ||
| Y | 35 | 60.0 | 0.93 (0.38-2.27) | .87 | 36 | 48.5 | 1.06 (0.67-1.66) | .81 |
| FFP | ||||||||
| N | 47 | 57.4 | Reference | 47 | 41 | Reference | ||
| Y | 71 | 60.6 | 1.30 (0.56-3.05) | .54 | 74 | 41 | 1.56 (0.99-2.37) | .05 |
| PE | ||||||||
| N | 86 | 58.1 | Reference | 88 | 42 | Reference | ||
| Y | 31 | 64.5 | 1.25 (0.49-3.23) | .64 | 32 | 40 | 1.41 (0.88-2.28) | .16 |
| Strategies . | N . | TA-TMA response . | N . | Post TA-TMA survival . | ||||
|---|---|---|---|---|---|---|---|---|
| Response rate, % . | OR (95% CI) . | P . | Median OS, d . | HR (95% CI) . | P . | |||
| Immunosuppressant modulation | ||||||||
| Maintenance/reduction of CNI | 85 | 64.7 | Reference | 86 | 50 | Reference | ||
| Switch to other CNIs | 11 | 72.7 | 1.42 (0.35-5.89) | .62 | 11 | 74 | 0.71 (0.35-1.44) | .34 |
| Switch to CS | 10 | 20.0 | 0.12 (0.02-0.63) | .01* | 11 | 17 | 3.23 (1.64-6.33) | <.01* |
| Increase of CS | 9 | 44.4 | 0.37 (0.09-1.59) | .18 | 10 | 36 | 1.71 (0.86-3.42) | .13 |
| rhTM | ||||||||
| N | 83 | 59.0 | Reference | 85 | 41 | Reference | ||
| Y | 35 | 60.0 | 0.93 (0.38-2.27) | .87 | 36 | 48.5 | 1.06 (0.67-1.66) | .81 |
| FFP | ||||||||
| N | 47 | 57.4 | Reference | 47 | 41 | Reference | ||
| Y | 71 | 60.6 | 1.30 (0.56-3.05) | .54 | 74 | 41 | 1.56 (0.99-2.37) | .05 |
| PE | ||||||||
| N | 86 | 58.1 | Reference | 88 | 42 | Reference | ||
| Y | 31 | 64.5 | 1.25 (0.49-3.23) | .64 | 32 | 40 | 1.41 (0.88-2.28) | .16 |
Statistically significant.